Clinical trial
A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of ANG-3777 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery
NCT02771509 is registered in ClinicalTrials.gov with Angion Biomedica Corp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of ANG-3777 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery
- Lead sponsor
- Angion Biomedica Corp
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 24, 2017
- Completion date
- August 31, 2021
- Enrollment
- 275 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.